ArticleFrontiers in microbiology2022
Phage-Derived Depolymerase as an Antibiotic Adjuvant Against Multidrug-Resistant
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2025Pooled it
- One-Step Immobilized Phage Depolymerase Coatings for Catheter-Related Bloodstream Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Progress of Bacteriophage Research and Application in the Treatment of Bovine Mastitis: A Review.Veterinary sciences · 2026Review
- DposFinder: an interpretable transformer model for predicting phage-derived polysaccharide depolymerases and their host capsular serotypes.Genome medicine · 2026Article
- Genome characterization and receptor-binding protein identification of Klebsiella phage vB_VIPKPNMC05, a member of a novel viral family Pituviridae.Archives of virology · 2026Article
- Phage-antibiotic synergy restores β-lactam efficacy in MDR Klebsiella quasipneumoniae biofilms and suppresses resistance.Journal of biomedical science · 2026Article
- Identification and characterization of Phi1 and Phi3 bacteriophages targeting Xylella fastidiosa subsp. pauca, the causal agent of olive quick decline in Italy.Scientific reports · 2026Article
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Identify and characterize a carbapenem-resistant Salmonella enteritidis phage depolymerase Dpo52.Scientific reports · 2026Article
- Next-Generation Strategies for Controlling Foodborne Pathogens: Precision Antimicrobials, Biofilm Disruption, and Emerging Molecular Interventions.Foods (Basel, Switzerland) · 2026Review
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Identification, resistance mechanisms, and innovative therapeutic approaches againstFrontiers in microbiology · 2026Review
- Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.Frontiers in cellular and infection microbiology · 2026Review
- Phage enabled precision drug delivery: dual function platforms for therapeutics and genetic cargo transport.Frontiers in microbiology · 2026Review
- Bacteriophages as an alternative strategy for the treatment of drug resistant bacterial infections: Current approaches and future perspectives.Cell surface (Amsterdam, Netherlands) · 2025Review
- A Novel, Broad-Spectrum, Virulent Bacteriophage TargetingPathogens (Basel, Switzerland) · 2025Article
- Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025Review
- Antibiotic-resistant Acinetobacter baumannii can be killed by a combination of bacteriophages and complement.Medical microbiology and immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophage-encoded depolymerases are responsible for degrading capsular polysaccharides (CPS), lipopolysaccharides (LPS), and exopolysaccharides (EPS) of the host bacteria during phage invasion. They have been considered as promising antivirulence agents in controlling bacterial infections, including those caused by multidrug-resistant (MDR) bacteria. This feature inspires hope of utilizing these enzymes to disarm the polysaccharide capsules of the bacterial cells, which then strengthens the action of antibiotics. Here we have identified, cloned, and expressed a depolymerase Dpo71 from a bacteriophage specific for the gram-negative bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.